Vocabria(Cabotegravir) Instructions:Uses,Dosage, Side Effects

HIV-1 Treatment: Indicated in combination with EDURANT (rilpivirine) for the short-term treatment of HIV-1 infection in virologically suppressed adults and adolescents (≥12 years, ≥35 kg) with no history of treatment failure and no known resistance to either drug. Used as an oral lead-in to assess tolerability prior to initiating CABENUVA injections or as oral therapy to cover planned missed injections.

HIV-1 PrEP: Indicated for short-term pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 in at-risk adults and adolescents (≥35 kg) with a confirmed negative HIV-1 status. Used as an oral lead-in prior to APRETUDE injections or to cover a planned missed injection.

HIV-1 Treatment: One 30 mg VOCABRIA tablet taken orally once daily with one 25 mg EDURANT tablet, administered with a meal. For oral lead-in, the duration is approximately 1 month (at least 28 days). To replace missed CABENUVA injections, oral therapy is used for up to 2 months.

HIV-1 PrEP: One 30 mg VOCABRIA tablet taken orally once daily. For oral lead-in, the duration is approximately 1 month (at least 28 days). To replace a missed APRETUDE injection, oral therapy is initiated approximately 2 months after the last injection.

Antacids containing polyvalent cations should be administered at least 2 hours before or 4 hours after VOCABRIA.